MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 551028 | Name: Shz-1
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Shz-1 is a novel activator of early cardiac genes (including Nkx2.5) in pluripotent stem cells. Shz-1 activates the axolotl TPM4 promoter-driven ectopic expression in C2C12 cells and the promoters of a variety of genes including axolotl TPM4.

Chemical Structure

Shz-1
Shz-1
CAS#326886-05-9

Theoretical Analysis

MedKoo Cat#: 551028

Name: Shz-1

CAS#: 326886-05-9

Chemical Formula: C13H11BrN2O3S

Exact Mass: 353.9674

Molecular Weight: 355.21

Elemental Analysis: C, 43.96; H, 3.12; Br, 22.50; N, 7.89; O, 13.51; S, 9.03

Price and Availability

Size Price Availability Quantity
1mg USD 300.00 2 Weeks
5mg USD 450.00 2 weeks
10mg USD 700.00 2 weeks
50mg USD 1,100.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Shz-1; Shz1; Shz 1
IUPAC/Chemical Name
Benzenesulfonic acid 2-[(5-bromo-2-hydroxyphenyl)methylene]hydrazide
InChi Key
OEMCLQLAWYKPRK-OQLLNIDSSA-N
InChi Code
InChI=1S/C13H11BrN2O3S/c14-11-6-7-13(17)10(8-11)9-15-16-20(18,19)12-4-2-1-3-5-12/h1-9,16-17H/b15-9+
SMILES Code
O=S(C1=CC=CC=C1)(N/N=C/C2=CC(Br)=CC=C2O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Shz-1 activates cardiac differentiation, inducing the expression of early cardiac genes in mouse pluripotent and embryonic stem cells in vitro at low micromolar concentrations. Shz-1 drives differentiation of human peripheral blood mononuclear cells, mobilized by granule colony-stimulating factor, toward a cardiac phenotype. Shz-1 treated cells enhance myocardial regenerative repair in cryo-injured rat heart.
In vitro activity:
Shz-1 increased cardiac Nkx2.5 gene transcripts and enhanced sarcomeric TPM1 and TPM4α in axolotl hearts. In C2C12 cells, Shz-1 activated axolotl TPM4 and mouse skeletal muscle troponin-I promoters, indicating broad gene activation. Notably, while shz-1 increased TM protein expression in C2C12 cells, it had no impact on axolotl hearts, supporting the idea of translational control in cardiac TM expression. Reference: Cardiovasc Toxicol. 2015 Jan;15(1):29-40. https://pubmed.ncbi.nlm.nih.gov/24958154/
In vivo activity:
Shz-1 increased cardiac Nkx2.5 gene transcripts and enhanced sarcomeric TPM1 and TPM4α in axolotl hearts. In C2C12 cells, Shz-1 activated axolotl TPM4 and mouse skeletal muscle troponin-I promoters, indicating broad gene activation. Notably, while shz-1 increased TM protein expression in C2C12 cells, it had no impact on axolotl hearts, supporting the idea of translational control in cardiac TM expression. Reference: Cardiovasc Toxicol. 2015 Jan;15(1):29-40. https://pubmed.ncbi.nlm.nih.gov/24958154/
Solvent mg/mL mM comments
Solubility
DMF 30.0 84.46
DMSO 30.0 84.46
Ethanol 30.0 84.46
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 355.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Nan C, Dube S, Matoq A, Mikesell L, Abbott L, Alshiekh-Nasany R, Chionuma H, Huang X, Poiesz BJ, Dube DK. Expression of sarcomeric tropomyosin in striated muscles in axolotl treated with shz-1, a small cardiogenic molecule. Cardiovasc Toxicol. 2015 Jan;15(1):29-40. doi: 10.1007/s12012-014-9265-z. PMID: 24958154.
In vitro protocol:
1. Nan C, Dube S, Matoq A, Mikesell L, Abbott L, Alshiekh-Nasany R, Chionuma H, Huang X, Poiesz BJ, Dube DK. Expression of sarcomeric tropomyosin in striated muscles in axolotl treated with shz-1, a small cardiogenic molecule. Cardiovasc Toxicol. 2015 Jan;15(1):29-40. doi: 10.1007/s12012-014-9265-z. PMID: 24958154.
In vivo protocol:
1. Nan C, Dube S, Matoq A, Mikesell L, Abbott L, Alshiekh-Nasany R, Chionuma H, Huang X, Poiesz BJ, Dube DK. Expression of sarcomeric tropomyosin in striated muscles in axolotl treated with shz-1, a small cardiogenic molecule. Cardiovasc Toxicol. 2015 Jan;15(1):29-40. doi: 10.1007/s12012-014-9265-z. PMID: 24958154.
1: Nan C, Dube S, Matoq A, Mikesell L, Abbott L, Alshiekh-Nasany R, Chionuma H, Huang X, Poiesz BJ, Dube DK. Expression of sarcomeric tropomyosin in striated muscles in axolotl treated with shz-1, a small cardiogenic molecule. Cardiovasc Toxicol. 2015 Jan;15(1):29-40. doi: 10.1007/s12012-014-9265-z. PubMed PMID: 24958154. 2: Tzabazis AZ, Klukinov M, Feliciano DP, Wilson SP, Yeomans DC. Gene therapy for trigeminal pain in mice. Gene Ther. 2014 Apr;21(4):422-6. doi: 10.1038/gt.2014.14. Epub 2014 Feb 27. PubMed PMID: 24572785; PubMed Central PMCID: PMC3975690. 3: Kang W, Wilson SP, Wilson MA. Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines. Neuropsychopharmacology. 2000 Jan;22(1):77-88. PubMed PMID: 10633493.